OZEM holdings
All 26 positions of Roundhill GLP-1 & Weight Loss ETF.
Positions
26
Top 10 weight
65.9%
Effective holdings
15.8
1 / sum of squared weights
In stocks
99.6%
In bonds
0.0%
Outside the US
55.4%
Asset mix
Sectors
57% of stocks classifiedCountries
Holdings
| # | Holding | Type | Weight | Value | Shares / par | Country |
|---|---|---|---|---|---|---|
| 1 | NVONovo-Nordisk A/S | Equity | 12.96% | $7.0M | 146,234 | DK |
| 2 | LLYEli Lilly & Co. | Equity | 12.69% | $6.9M | 5,722 | US |
| 3 | Mount Vernon Liquid Assets Portfolio, LLC | Cash | 9.93% | $5.4M | 5,371,408 | US |
| 4 | PFEPfizer Inc. | Equity | 6.38% | $3.5M | 143,389 | US |
| 5 | KLRAKailera Therapeutics, Inc. Common Stock | Equity | 6.21% | $3.4M | 152,501 | US |
| 6 | VKTXViking Therapeutics, Inc | Equity | 5.86% | $3.2M | 81,186 | US |
| 7 | CSPC Pharmaceutical Group Ltd | Equity | 5.32% | $2.9M | 3,236,000 | CN |
| 8 | Chugai Pharmaceutical Co Ltd | Equity | 4.51% | $2.4M | 52,600 | JP |
| 9 | Ascletis Pharma Inc | Equity | 4.20% | $2.3M | 1,686,000 | CN |
| 10 | Zealand Pharma A/S | Equity | 3.92% | $2.1M | 47,873 | DK |
| 11 | AMGNAmgen Inc | Equity | 3.85% | $2.1M | 5,750 | US |
| 12 | AstraZeneca PLC | Equity | 3.83% | $2.1M | 10,931 | GB |
| 13 | Hanmi Pharm Co Ltd | Equity | 3.50% | $1.9M | 7,386 | KR |
| 14 | GPCRStructure Therapeutics Inc. American Depositary Shares | Equity | 3.05% | $1.7M | 30,773 | US |
| 15 | Roche Holding AG | Equity | 3.03% | $1.6M | 3,972 | CH |
| 16 | MBXMBX Biosciences, Inc. Common Stock | Equity | 2.80% | $1.5M | 27,421 | US |
| 17 | UNITED LAB | Equity | 2.63% | $1.4M | 1,322,000 | HK |
| 18 | Jiangsu Hengrui Pharmaceutical | Equity | 2.58% | $1.4M | 189,200 | CN |
| 19 | Hansoh Pharmaceutical Group Co | Equity | 2.54% | $1.4M | 364,000 | CN |
| 20 | Innovent Biologics Inc | Equity | 2.36% | $1.3M | 126,000 | CN |
| 21 | Gubra A/S | Equity | 1.87% | $1.0M | 20,597 | DK |
| 22 | GILDGilead Sciences Inc | Equity | 1.73% | $938K | 7,425 | US |
| 23 | RYTMRhythm Pharmaceuticals, Inc. Common Stock | Equity | 1.64% | $884K | 7,966 | US |
| 24 | Shionogi & Co Ltd | Equity | 1.24% | $671K | 39,100 | JP |
| 25 | WaVe Life Sciences Ltd | Equity | 0.86% | $467K | 80,432 | SG |
| 26 | First American Government Obli | Cash | 0.62% | $335K | 335,006 | US |
Find which other funds hold a stock by opening it and choosing "ETFs holding".
Position changes between reports
| Action | Holding | Weight before | Weight after | Shares vs flows | Between reports |
|---|---|---|---|---|---|
| New position | KLRAKailera Therapeutics Inc | — | 6.21% | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | LLYEli Lilly & Co | 16.10% | 12.69% | −34.6% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Exit | REGNRegeneron Pharmaceuticals Inc | 3.33% | — | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Exit | FOSUN PHARMA | 3.26% | — | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | Innovent Biologics Inc | 5.11% | 2.37% | −46.5% | Mar 31, 2026 → Jun 30, 2026 SEC |
| New position | Jiangsu Hengrui Pharmaceutical | — | 2.58% | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| New position | Hansoh Pharmaceutical Group Co | — | 2.54% | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | CSPC Pharmaceutical Group Ltd | 2.93% | 5.32% | +156.6% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | Chugai Pharmaceutical Co Ltd | 3.45% | 4.51% | +65.1% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | Roche Holding AG | 3.92% | 3.03% | −20.5% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Exit | Biohaven Ltd | 0.87% | — | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | MBXMBX Biosciences Inc | 1.99% | 2.80% | −17.6% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | GPCRStructure Therapeutics Inc | 2.38% | 3.05% | +24.8% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | Ascletis Pharma Inc | 4.67% | 4.20% | +53.2% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Exit | CRBPCorbus Pharmaceuticals Holding | 0.40% | — | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | WaVe Life Sciences Ltd | 0.46% | 0.86% | +152.6% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | UNITED LAB | 2.27% | 2.63% | +42.6% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | Zealand Pharma A/S | 3.60% | 3.92% | +21.1% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | NVONovo Nordisk A/S | 13.13% | 12.96% | −18.1% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | Hanmi Pharm Co Ltd | 3.66% | 3.50% | +35.9% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | Shionogi & Co Ltd | 1.39% | 1.24% | +23.1% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | AstraZeneca PLC | 3.76% | 3.83% | +14.6% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Exit | Roche Holding AG | 4.19% | — | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| New position | Roche Holding AG | — | 3.92% | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| New position | AstraZeneca PLC | — | 3.76% | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | PFEPfizer Inc | 4.00% | 7.56% | +63.8% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Exit | AZNAstraZeneca PLC | 3.20% | — | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| New position | MBXMBX Biosciences Inc | — | 1.99% | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | Innovent Biologics Inc | 3.15% | 5.11% | +43.4% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Exit | SRRKScholar Rock Holding Corp | 1.93% | — | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | GPCRStructure Therapeutics Inc | 4.08% | 2.38% | −17.7% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | CSPC Pharmaceutical Group Ltd | 1.93% | 2.93% | +38.4% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | Zealand Pharma A/S | 4.55% | 3.60% | +24.7% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | Biohaven Ltd | 1.77% | 0.87% | −35.7% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | VKTXViking Therapeutics Inc | 4.41% | 5.29% | +26.7% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | Chugai Pharmaceutical Co Ltd | 3.96% | 3.45% | −17.3% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | REGNRegeneron Pharmaceuticals Inc | 2.84% | 3.33% | +14.6% | Dec 31, 2025 → Mar 31, 2026 SEC |
| New position | CRBPCorbus Pharmaceuticals Holding | — | 0.40% | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | UNITED LAB | 2.04% | 2.27% | +32.6% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | Gubra A/S | 2.60% | 2.42% | +35.1% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | LLYEli Lilly & Co | 16.02% | 16.10% | +14.8% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | RYTMRhythm Pharmaceuticals Inc | 1.47% | 1.43% | +17.3% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | GILDGilead Sciences Inc | 1.89% | 1.91% | −13.2% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | Shionogi & Co Ltd | 1.40% | 1.39% | −19.4% | Dec 31, 2025 → Mar 31, 2026 SEC |
Share-count changes are measured after removing what creations and redemptions explain.
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.